F m Investments LLC Acquires 8,627 Shares of TransMedics Group, Inc. $TMDX

F m Investments LLC grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 15.2% in the fourth quarter, Holdings Channel reports. The firm owned 65,539 shares of the company’s stock after buying an additional 8,627 shares during the quarter. F m Investments LLC’s holdings in TransMedics Group were worth $7,973,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new stake in shares of TransMedics Group in the 3rd quarter worth $29,000. Allworth Financial LP increased its holdings in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. Optiver Holding B.V. increased its holdings in shares of TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares in the last quarter. Finally, LOM Asset Management Ltd bought a new stake in shares of TransMedics Group in the 3rd quarter worth $34,000. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. TD Cowen reduced their target price on TransMedics Group from $190.00 to $120.00 and set a “buy” rating for the company in a report on Wednesday. Canaccord Genuity Group dropped their price target on TransMedics Group from $152.00 to $124.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Stifel Nicolaus dropped their price target on TransMedics Group from $130.00 to $85.00 and set a “hold” rating on the stock in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average price target of $135.00.

TransMedics Group Price Performance

NASDAQ TMDX opened at $68.00 on Friday. The company has a market capitalization of $2.35 billion, a PE ratio of 15.45 and a beta of 2.07. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.59 and a current ratio of 6.74. The business’s fifty day moving average is $114.04 and its 200 day moving average is $125.34. TransMedics Group, Inc. has a fifty-two week low of $67.69 and a fifty-two week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). The company had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. TransMedics Group’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.70 earnings per share. Sell-side analysts predict that TransMedics Group, Inc. will post 2.22 earnings per share for the current year.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 864 shares of TransMedics Group stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $120,199.68. Following the transaction, the insider directly owned 13,091 shares in the company, valued at approximately $1,821,219.92. The trade was a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Weill sold 3,571 shares of TransMedics Group stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total value of $524,294.22. Following the transaction, the director owned 12,134 shares in the company, valued at $1,781,513.88. This trade represents a 22.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,205 shares of company stock valued at $2,353,002 in the last ninety days. Corporate insiders own 6.90% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.